Related Experiment Video
Updated: Jun 26, 2025
07:02
Identifying Dysregulated Genes Induced by Kaposi's Sarcoma-associated Herpesvirus KSHV
Published on: September 14, 2010
12.6K
Prognostic factors in Kaposi sarcoma, single centre experience
Ezgi Değerli1, Kerem Oruç2, Nihan Şentürk Öztaş3
1Department of Medical Oncology, Bakırköy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey.
The Australasian Journal of Dermatology
|May 18, 2024
Summary
Classical Kaposi sarcoma (CKS) prognosis is poor in male patients with low hemoglobin or disseminated disease. This Turkish study identified key prognostic factors for this rare cancer.
Area of Science:
- Oncology
- Virology
- Dermatology
Background:
- Kaposi sarcoma (KS) is a vascular and lymphatic neoplasm caused by human herpesvirus 8 (HHV-8).
- Classical Kaposi sarcoma (CKS) is the most common subtype, primarily affecting elderly and immunosuppressed individuals.
- Understanding CKS subtypes is crucial for targeted treatment strategies.
Purpose of the Study:
- To define prognostic subgroups among patients with Classical Kaposi sarcoma (CKS).
- To identify factors influencing survival in CKS patients.
- To provide insights into CKS prognosis in the Turkish population.
Main Methods:
- Retrospective study of 43 CKS patients treated between 2014 and 2020.
- Data collected included demographics, clinical features, laboratory findings, and treatment responses.
- Analysis focused on overall survival and prognostic indicators.
Main Results:
- Eight patients (18.6%) died from CKS during follow-up.
- Complete response rate was 46.5%; partial response/stable disease was 51.2%.
- Male gender, low hemoglobin, and disseminated disease were significant prognostic factors for survival.
Conclusions:
- Male gender, low hemoglobin levels, and disseminated disease are associated with a poor prognosis in CKS.
- This study is the first Turkish research to perform prognostic analysis for CKS.
- Identifying prognostic factors aids in risk stratification and personalized treatment of CKS.
More Related Videos
Related Concept Videos
01:21Cancer Survival Analysis
343
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
343
01:24Kaplan-Meier Approach
132
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
132
01:20Comparing the Survival Analysis of Two or More Groups
177
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
177